Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for kidney transplant patients facing advanced skin cancer

NCT ID NCT03816332

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 23 times

Summary

This early-stage study tests a combination of drugs (tacrolimus, nivolumab, and ipilimumab) in 12 kidney transplant recipients who have advanced skin cancers that cannot be surgically removed. The goal is to see if this treatment can shrink or control the cancer while keeping the transplanted kidney working. Participants must have a functioning kidney transplant and not be on dialysis.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland, 21287, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Moffitt Cancer Center - McKinley Campus

    Tampa, Florida, 33612, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • University of Pittsburgh Cancer Institute (UPCI)

    Pittsburgh, Pennsylvania, 15232, United States

Conditions

Explore the condition pages connected to this study.